Compare TG Therapeutics Inc (TGTX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $54.85 (market cap $8.16B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.17 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 16.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is more actively traded (1,735,121 versus 1,287,188). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| TGTX | VIG | |
|---|---|---|
Market Cap | $8.16B | $132.40B |
Volume | 1,735,121 | 1,287,188 |
Sector | Health | — |
52-Week High | $59.06 | $246.61 |
52-Week Low | $26.94 | $210.70 |
Typical Hold Time | 16 Days | 134 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VIG trades at $239.00, up 0.85% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its role in retirement portfolios and a 7.5% quarterly dividend increase, though year-to-date growth remains modest at 3.3%.
Outlook remains positive given VIG's quality focus and historical 10% annual returns, but risks include slow dividend growth and exclusion of high-yield stocks. The ETF suits investors seeking steady income with growth potential, though competition from SCHD and market volatility pose challenges to outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
